Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 50 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
PHARMA BURY & CO from Anderlues, company number BE0723851414, closed financial year 2025 with a result of € 10,452 after tax. For that financial year PHARMA BURY & CO recorded a gross margin of € 190,483 and equity of € 64,178. Compared with financial year 2024, the result moved from € 19,182 to € 10,452. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 27, 2026.
€ 64,178
▲ 19% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 10,452
▼ 46% vs 2024
Profit after tax over the fiscal year.
€ 48,176
▼ 2% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 14,178.
People and assets in 2025
1.1
Average over the fiscal year, from the social balance sheet.
€ 60,868
▲ 69% vs 2024
€ 55,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 2,361
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 1.4 million
▲ 148% vs 2024
€ 133,789 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.
€ 149,228
▲ 49% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 17,794
▼ 50% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 149,231 | € 162,239 | € 186,153 | € 190,483 | ▲ 2% |
| Profit after taxes | € 2,324 | € 10,961 | € 19,182 | € 10,452 | ▼ 46% |
| Equity | € 23,583 | € 34,544 | € 53,726 | € 64,178 | ▲ 19% |
| Total debts | € 811,151 | € 824,273 | € 705,907 | € 1,569,344 | ▲ 122% |
| Cash | € 71,678 | € 67,943 | € 48,966 | € 48,176 | ▼ 2% |
| Land & buildings | € 100,701 | € 114,517 | € 107,685 | € 91,222 | ▼ 15% |
| Retained profit | € -26,417 | € -15,456 | € 3,726 | € 14,178 | ▲ 281% |
| Bank debt | € 638,607 | € 605,122 | € 564,489 | € 1,397,388 | ▲ 148% |
| Balance sheet total | € 834,734 | € 858,817 | € 759,633 | € 1,633,522 | ▲ 115% |
| Employees (FTE) | 0.6 | 0.6 | 0 | 1.1 |
Key figures of PHARMA BURY & CO, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMA BURY & CO?
What happened at PHARMA BURY & CO in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 10,452 (▼ 46% vs 2024). filed late Source: NBB ↗
- Amélie BURY became a director. NBB
- Manon BURY became a director. NBB
- New establishment in Binche. KBO
- Start of the company according to the CBE. KBO
In short
From € 2,324 profit in 2022 to € 10,452 profit in 2025.
Paid € 90,744 in corporate taxes since 2022.
Best year ever: 2024, with € 19,182 profit.
On average € 173,200 of value added per employee in 2025.
A new publication or filing at PHARMA BURY & CO? We notify you, reason included.
Follow PHARMA BURY & CODatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PHARMA BURY & CO are Amélie BURY and Manon BURY. Manon BURY is also behind PHARMACIE DE LA TOUR.
Directors
According to the 2025 annual accounts
Amélie BURY
Director
since 2020
since 2020
Establishments
Establishment units
Physical locations of this company
Place Albert Ier 2
6150 Anderlues
Rue du Bois d'Hamal(LEV) 30
7134 Binche
Active since 1 April 2019
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0723.851.414
- VAT number
- BE 0723.851.414
- Registered office
- Place Albert Ier 2, 6150 Anderlues
- Names & denominations
- PHARMA BURY & CO
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 1 April 2019
- Peppol
- Active · Active since 2 Sept 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Detailhandel in cosmetica en toiletartikelen